Jun 03, 2023
CEO Peter Buhl comments: “CHOSA presents these important findings that have crystallized by deep clinical knowledge and years of dedication to developing LiPlaCis and its response prediction test DRP”.
We welcome interaction and look forward to discussing this at the ASCO poster session that opens today:
Abstract number and title: 3130; Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster Board: 328
Date and time: Saturday 3 June 2023; 8:00-11:00 CDT
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-06-2023 15:00 CET.